Scholars Central

Research articlePublished 2015

Liraglutide Effect on Blood Pressure, Lipids Profile, and Liver Enzymes in Arab Patients with Type 2 Diabetes Mellitus: A Prospective LIRA-BPL Study

Authors: Elamin Ibrahim Elamin Abdelgadir, Alaaeldin MK Bashier, Fatheya F Al Awadi, Ahmed Tarig Altinay, Mohamed Abdelatif Elsayed, Azza Abdulaziz Khalifa, Fauzia Rashid, Suada Makeen

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: The pathogenetic mechanisms underlying type2 diabetes are quite complex and differ between different ethnic groups. This might results in different responses to medications. Data from LEAD trials showed that liraglutide was associated with significant reduction in weight HbA1c and blood pressure values. Unfortunately there are no enough data on Arab population. Objectives: We aimed to assess the changes in blood pressure, lipids profile, and liver function test upon starting liraglutide and after 6 months of therapy in Arab patients with type 2 diabetes as primary objective. Results: 365 agreed to sign an informed consent. 29% of the studied population was males (n=106) compared to 71% females (n=259). There was no significant change in systolic blood pressure, however average diastolic blood pressure improved significantly (74.4 ± 10 to 72 ± 9 mmHg at 6 months P<0.001). Significantly lower average diastolic BP was seen in Insulin users at both start and the end of the study (73+4 vs. 76+4 P=0.05, and (71+ 5 vs. 73+4.6) p=0.02, respectively). Mean AST and ALT was within normal range at baseline and despite that there was a highly significant reduction between baseline and end of study 29+18 to 25.7+ 13 and 25.1 + 20 to 22.2+ 16 for ALT and AST, respectively. Both of them showed highly significant P value (0.0000). There was a significant reduction in weight and HbA1c at 6 months. However the change in weight was more significant in insulin users compared to those who did not use insulin (96+3 to 93+5 vs. 93 +5 to 98+3.5, P-value at the end of the study was 0.02). The HbA1c reduction was significant irrespective of weight loss. Conclusion: Liraglutide showed remarkable improvement in weight, HbA1c, liver enzymes, and diastolic blood pressure. Patients who used insulin at base line had better results in weight and lipids reduction. ALT: Alanine Aminotransferase; AST: Aspartate Transaminase; GLP-1: Glucagon-Like Peptide; GFR: Glomerular Filtration Rate; SPSS: Statistical Program for Social Science Liraglutide has been proved to be an efficacious agent among the GLP-1 agonists-its effect on glucose control, weight reduction, blood pressure reduction, and modulation of metabolic parameters [4-7]. But, to our best knowledge, it was not tested on the Arab population separately. Since many pharmacological agents showed different effects in different races, we conducted this study on patients from Arabic backgrounds looking into the efficacy of Liraglutide in modulating the blood pressure and metabolic parameters.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectDiabetes & Endocrinology
  • SubjectHaematology
  • SubjectBiochemistry & Biotechnology
  • BylineArticles whose byline prints “Elamin Ibrahim Elamin Abdelgadir”
  • BylineArticles whose byline prints “Alaaeldin MK Bashier”
  • BylineArticles whose byline prints “Fatheya F Al Awadi”
  • BylineArticles whose byline prints “Ahmed Tarig Altinay”
  • BylineArticles whose byline prints “Mohamed Abdelatif Elsayed”
  • BylineArticles whose byline prints “Azza Abdulaziz Khalifa”
  • BylineArticles whose byline prints “Fauzia Rashid”
  • BylineArticles whose byline prints “Suada Makeen”